Acquired EGFR T790M Mutation in NSCLC: Testing in FFPE Tissue
Recorded On: 04/22/2020
Recent advancements for improving outcomes in NSCLC include immunotherapy treatments developed through genetic testing. EGFR mutations have been identified as a significant cause of poor response in a subset of NSCLC patients. FDA testing methods are now available using formalin-fixed paraffin embedded tissue to identify these mutations, and other genetic aberrations. The EGFR pathway, angiogenesis, tyrosine-kinase inhibitors, and in-vitro testing on FFPE tissue will be discussed.
Jane Ann Wade, HT(ASCP)MLT
Professor, Medical Laboratory Science
- Ms. Wade is an instructor at West Virginia University, in the Medical Laboratory Science Department where she teaches and coordinates many courses, including those involving Histotechniques. She is also a presenter at both national and state conferences, and over the years has served on various committees and workgroups such as the NSH Education Committee, the Medical Laboratory Science Admissions Committee, the Pathologists Assistant Admission Committee, and creating trainings for the Tropical Medicine Laboratory. Prior to her work with the University of West Virginia, Ms. Wade was the Histopathology Technical Manager at Monongalia General Hospital where Managed Histology, Cytology, and Pathology Transcription Quality Assurance and Quality Control; and many other projects.